AB
ABT
Quarter ended Jun 30, 2024 · FY2024 Q2

Abbott Laboratories (ABT) Revenue — Quarter Ended Jun 30, 2024

Revenue for the quarter increased compared to both the prior quarter and the same quarter last year. The sequential gain reflects continued growth momentum, while the year-over-year rise aligns with the prior year's pace.

Key takeaway

Quarter ended Jun 30, 2024 · FY2024 Q2

Revenue for the quarter increased compared to both the prior quarter and the same quarter last year. The sequential gain reflects continued growth momentum, while the year-over-year rise aligns with the prior year's pace.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$10.4B

Revenue reported for this quarter.

Quarter-over-quarter

+4.1%

Change from the immediately preceding quarter.

Year-over-year

+4.0%

Change from the comparable year-ago quarter.

Trailing four quarters

$40.7B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Sep 30, 2023$10.1B-2.6%
Dec 31, 2023$10.2B+1.5%
Mar 31, 2024$10B+2.2%
Jun 30, 2024$10.4B+4.0%

Revenue performance

Reported revenue moved higher from the preceding quarter, marking a third consecutive sequential increase. The rate of growth accelerated slightly compared to the prior quarter.

Quarterly comparison

When compared with the same quarter a year ago, revenue also showed an increase, maintaining a similar growth rate. The filing context does not provide specific causes for these movements.

What to watch

No forward-looking guidance or material risk factors directly tied to revenue were disclosed in the filing context.